{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:29:39Z","timestamp":1794619779987,"version":"4.9.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    High-grade serous ovarian cancer (HGSOC) is characterized by extensive transcoelomic dissemination and the accumulation of ascites. However, how site-specific tumor microenvironment (TME) drives progression remains unknown. Here we show the co-occurrence and spatial co-localization of\n                    <jats:italic>SELENOP<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    macrophages and precursor exhausted CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and demonstrate that\n                    <jats:italic>SELENOP<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    macrophages activate T cells via selenoprotein P in vitro and in vivo. We further identify a dynamic transition in the\n                    <jats:italic>SELENOP<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    \/\n                    <jats:italic>SPP1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    macrophage populations as tumor metastasis, driven by increased hypoxia malignant epithelial cells through VEGFA-EPHB2 signaling. We also reveal that anti-VEGFA intervention controls ovarian tumor growth by increasing\n                    <jats:italic>SELENOP<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    macrophages and cytotoxicity of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in vivo. Taken together, these findings spotlight the role of tumor-induced TME remodeling in subverting immune-mediated tumor control and thus facilitating HGSOC metastasis in females. Collectively, our results provide a foundation for the development of targeted therapeutic interventions aimed at impeding HGSOC metastatic trajectory.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-67859-2","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:08:49Z","timestamp":1768230529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hypoxia-driven remodeling of SELENOP+ macrophages shapes T cell dynamics and promotes ovarian cancer metastasis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-8531","authenticated-orcid":false,"given":"Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-7768","authenticated-orcid":false,"given":"Chenzhao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7241-1944","authenticated-orcid":false,"given":"Tianhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0621-4856","authenticated-orcid":false,"given":"Siyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7874-6324","authenticated-orcid":false,"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0124-1258","authenticated-orcid":false,"given":"Xueying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6668-8326","authenticated-orcid":false,"given":"Shuangyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1609-4275","authenticated-orcid":false,"given":"Linru","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7519-0572","authenticated-orcid":false,"given":"Yuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5430-2868","authenticated-orcid":false,"given":"Shimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-2773","authenticated-orcid":false,"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-6594","authenticated-orcid":false,"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-7152","authenticated-orcid":false,"given":"Xuanzhang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-1638","authenticated-orcid":false,"given":"Chaoyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-7304","authenticated-orcid":false,"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"67859_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"67859_CR2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/cncr.21310","volume":"104","author":"LH Smith","year":"2005","unstructured":"Smith, L. H. et al. Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 104, 1398\u20131407 (2005).","journal-title":"Cancer"},{"key":"67859_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan, D. S., Agarwal, R. & Kaye, S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925\u2013934 (2006).","journal-title":"Lancet Oncol."},{"key":"67859_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford, C. E., Werner, B., Hacker, N. F. & Warton, K. The untapped potential of ascites in ovarian cancer research and treatment. Br. J. Cancer 123, 9\u201316 (2020).","journal-title":"Br. J. Cancer"},{"key":"67859_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl. Cancer Inst. 111, 60\u201368 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"67859_CR6","doi-asserted-by":"publisher","first-page":"m3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki, L. & Guntupalli, S. R. Treatment of epithelial ovarian cancer. BMJ 371, m3773 (2020).","journal-title":"BMJ"},{"key":"67859_CR7","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"67859_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275\u20131289 (2021).","journal-title":"Lancet Oncol."},{"key":"67859_CR9","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"67859_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245\u2013251 (2010).","journal-title":"Lancet"},{"key":"67859_CR11","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512\u20132519 (2010).","journal-title":"J. Clin. Oncol."},{"key":"67859_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1084\/jem.20180765","volume":"216","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 216, 688\u2013703 (2019).","journal-title":"J. Exp. Med."},{"key":"67859_CR13","first-page":"687","volume":"53","author":"A Hagiwara","year":"1993","unstructured":"Hagiwara, A. et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 53, 687\u2013692 (1993).","journal-title":"Cancer Res."},{"key":"67859_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758\u2013767 (2016).","journal-title":"Nat. Genet."},{"key":"67859_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100856","volume":"3","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep. Med. 3, 100856 (2022).","journal-title":"Cell Rep. Med."},{"key":"67859_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"67859_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107712","volume":"26","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites. iScience 26, 107712 (2023).","journal-title":"iScience"},{"key":"67859_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"67859_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy?. Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"67859_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"67859_CR21","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu, Y. et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med. 29, 1550\u20131562 (2023).","journal-title":"Nat. Med."},{"key":"67859_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng, X. et al. Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat. Cancer 4, 1138\u20131156 (2023).","journal-title":"Nat. Cancer"},{"key":"67859_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"67859_CR24","doi-asserted-by":"publisher","first-page":"eabd5778","DOI":"10.1126\/sciimmunol.abd5778","volume":"6","author":"P Gueguen","year":"2021","unstructured":"Gueguen, P. et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer. Sci. Immunol. 6, eabd5778 (2021).","journal-title":"Sci. Immunol."},{"key":"67859_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8(+) T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"67859_CR26","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1084\/jem.20180684","volume":"215","author":"J Brummelman","year":"2018","unstructured":"Brummelman, J. et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors. J. Exp. Med. 215, 2520\u20132535 (2018).","journal-title":"J. Exp. Med."},{"key":"67859_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"67859_CR28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"67859_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5603\/GP.2019.0032","volume":"90","author":"MM Dutsch-Wicherek","year":"2019","unstructured":"Dutsch-Wicherek, M. M. et al. Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes. Ginekol. Pol. 90, 179\u2013184 (2019).","journal-title":"Ginekol. Pol."},{"key":"67859_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3892\/mmr.2014.2893","volume":"11","author":"J Liu","year":"2015","unstructured":"Liu, J., Zhang, H., Jia, L. & Sun, H. Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions. Mol. Med. Rep. 11, 1708\u20131714 (2015).","journal-title":"Mol. Med. Rep."},{"key":"67859_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942\u2013949 (2004).","journal-title":"Nat. Med."},{"key":"67859_CR32","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308.e36 (2018).","journal-title":"Cell"},{"key":"67859_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829\u2013845.e20 (2019).","journal-title":"Cell"},{"key":"67859_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809.e23 (2021).","journal-title":"Cell"},{"key":"67859_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","volume":"41","author":"M Kilian","year":"2023","unstructured":"Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235\u2013251.e9 (2023).","journal-title":"Cancer Cell"},{"key":"67859_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112732","volume":"42","author":"MT Patterson","year":"2023","unstructured":"Patterson, M. T. et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 42, 112732 (2023).","journal-title":"Cell Rep."},{"key":"67859_CR37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","volume":"39","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell 39, 1361\u20131374.e9 (2021).","journal-title":"Cancer Cell"},{"key":"67859_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41587-021-01139-4","volume":"40","author":"V Kleshchevnikov","year":"2022","unstructured":"Kleshchevnikov, V. et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat. Biotechnol. 40, 661\u2013671 (2022).","journal-title":"Nat. Biotechnol."},{"key":"67859_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45595-3","volume":"15","author":"M Licaj","year":"2024","unstructured":"Licaj, M. et al. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway. Nat. Commun. 15, 1312 (2024).","journal-title":"Nat. Commun."},{"key":"67859_CR40","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","volume":"54","author":"D Barkley","year":"2022","unstructured":"Barkley, D. et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat. Genet. 54, 1192\u20131201 (2022).","journal-title":"Nat. Genet."},{"key":"67859_CR41","doi-asserted-by":"publisher","first-page":"e155022","DOI":"10.1172\/jci.insight.155022","volume":"7","author":"M Modak","year":"2022","unstructured":"Modak, M. et al. CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity. JCI Insight 7, e155022 (2022).","journal-title":"JCI Insight"},{"key":"67859_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1073\/pnas.90.2.537","volume":"90","author":"KE Hill","year":"1993","unstructured":"Hill, K. E., Lloyd, R. S. & Burk, R. F. Conserved nucleotide sequences in the open reading frame and 3\u2019 untranslated region of selenoprotein P mRNA. Proc. Natl. Acad. Sci. USA 90, 537\u2013541 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67859_CR43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"67859_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41417-023-00704-0","volume":"31","author":"J Wu","year":"2024","unstructured":"Wu, J., Shen, Y., Zeng, G., Liang, Y. & Liao, G. SPP1(+) TAM subpopulations in tumor microenvironment promote intravasation and metastasis of head and neck squamous cell carcinoma. Cancer Gene Ther. 31, 311\u2013321 (2024).","journal-title":"Cancer Gene Ther."},{"key":"67859_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00564-3","volume":"8","author":"G Fan","year":"2024","unstructured":"Fan, G. et al. Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ Precis. Oncol. 8, 75 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"67859_CR46","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin. Cancer Res. 28, 3590\u20133602 (2022).","journal-title":"Clin. Cancer Res."},{"key":"67859_CR47","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/ni.2304","volume":"13","author":"H Xu","year":"2012","unstructured":"Xu, H. et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13, 642\u2013650 (2012).","journal-title":"Nat. Immunol."},{"key":"67859_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler, I. J. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat. Rev. Cancer 3, 453\u2013458 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"67859_CR49","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.cell.2024.04.032","volume":"187","author":"AS Patel","year":"2024","unstructured":"Patel, A. S. & Yanai, I. A developmental constraint model of cancer cell states and tumor heterogeneity. Cell 187, 2907\u20132918 (2024).","journal-title":"Cell"},{"key":"67859_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13423","volume":"56","author":"D Li","year":"2023","unstructured":"Li, D. et al. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif. 56, e13423 (2023).","journal-title":"Cell Prolif."},{"key":"67859_CR51","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"67859_CR52","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar, B. et al. A single-cell landscape of high-grade serous ovarian cancer. Nat. Med. 26, 1271\u20131279 (2020).","journal-title":"Nat. Med."},{"key":"67859_CR53","doi-asserted-by":"publisher","first-page":"626229","DOI":"10.3389\/fcell.2021.626229","volume":"9","author":"M Tang","year":"2021","unstructured":"Tang, M., Bolderson, E., O\u2019Byrne, K. J. & Richard, D. J. Tumor hypoxia drives genomic instability. Front. Cell Dev. Biol. 9, 626229 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"67859_CR54","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","volume":"132","author":"EE Wicks","year":"2022","unstructured":"Wicks, E. E. & Semenza, G. L. Hypoxia-inducible factors: cancer progression and clinical translation. J. Clin. Invest. 132, e159839 (2022).","journal-title":"J. Clin. Invest."},{"key":"67859_CR55","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2023.06.005","volume":"41","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell 41, 1407\u20131426.e9 (2023).","journal-title":"Cancer Cell"},{"key":"67859_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","volume":"175","author":"M Angelova","year":"2018","unstructured":"Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751\u2013765.e16 (2018).","journal-title":"Cell"},{"key":"67859_CR57","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1158\/0008-5472.CAN-23-0379","volume":"83","author":"DT Weed","year":"2023","unstructured":"Weed, D. T. et al. The tumor immune microenvironment architecture correlates with risk of recurrence in head and neck squamous cell carcinoma. Cancer Res. 83, 3886\u20133900 (2023).","journal-title":"Cancer Res."},{"key":"67859_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410098","volume":"12","author":"C Mu","year":"2025","unstructured":"Mu, C. et al. Spatial transcriptome and single nucleus transcriptome sequencing reveals tetrahydroxy stilbene glucoside promotes ovarian organoids development through the Vegfa-Ephb2 Pair. Adv. Sci. 12, e2410098 (2025).","journal-title":"Adv. Sci."},{"key":"67859_CR59","doi-asserted-by":"publisher","first-page":"788587","DOI":"10.3389\/fcell.2022.788587","volume":"10","author":"W Liu","year":"2022","unstructured":"Liu, W., Yu, C., Li, J. & Fang, J. The roles of EphB2 in cancer. Front. Cell Dev. Biol. 10, 788587 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"67859_CR60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"67859_CR61","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473\u20132483 (2011).","journal-title":"N. Engl. J. Med."},{"key":"67859_CR62","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484\u20132496 (2011).","journal-title":"N. Engl. J. Med."},{"key":"67859_CR63","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","volume":"42","author":"IM Launonen","year":"2024","unstructured":"Launonen, I. M. et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell 42, 2045\u20132063.e10 (2024).","journal-title":"Cancer Cell"},{"key":"67859_CR64","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller, R. E. et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann. Oncol. 31, 1606\u20131622 (2020).","journal-title":"Ann. Oncol."},{"key":"67859_CR65","doi-asserted-by":"publisher","first-page":"e005627","DOI":"10.1136\/jitc-2022-005627","volume":"11","author":"L Ding","year":"2023","unstructured":"Ding, L. et al. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J. Immunother. Cancer 11, e005627 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"67859_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28389-3","volume":"13","author":"IM Launonen","year":"2022","unstructured":"Launonen, I. M. et al. Single-cell tumor-immune microenvironment of BRCA1\/2 mutated high-grade serous ovarian cancer. Nat. Commun. 13, 835 (2022).","journal-title":"Nat. Commun."},{"key":"67859_CR67","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","volume":"14","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand, F., Clemence Wei Xian, L. & Tan, D. S. P. Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol. 14, 1328651 (2023).","journal-title":"Front. Immunol."},{"key":"67859_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41392-022-01130-8","volume":"7","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct. Target Ther. 7, 289 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"67859_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev-nutr-071714-034250","volume":"35","author":"RF Burk","year":"2015","unstructured":"Burk, R. F. & Hill, K. E. Regulation of selenium metabolism and transport. Annu. Rev. Nutr. 35, 109\u2013134 (2015).","journal-title":"Annu. Rev. Nutr."},{"key":"67859_CR70","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bbagen.2009.03.026","volume":"1790","author":"RF Burk","year":"2009","unstructured":"Burk, R. F. & Hill, K. E. Selenoprotein P-expression, functions, and roles in mammals. Biochim. Biophys. Acta 1790, 1441\u20131447 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"67859_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105009","volume":"299","author":"A Mizuno","year":"2023","unstructured":"Mizuno, A. et al. An efficient selenium transport pathway of selenoprotein P utilizing a high-affinity ApoER2 receptor variant and being independent of selenocysteine lyase. J. Biol. Chem. 299, 105009 (2023).","journal-title":"J. Biol. Chem."},{"key":"67859_CR72","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627\u20131651 (2023).","journal-title":"Cell"},{"key":"67859_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song, M. et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat. Commun. 11, 6298 (2020).","journal-title":"Nat. Commun."},{"key":"67859_CR74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-017-0408-0","volume":"10","author":"Y Chen","year":"2017","unstructured":"Chen, Y., Zhang, S., Wang, Q. & Zhang, X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J. Hematol. Oncol. 10, 36 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"67859_CR75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Target Ther. 6, 75 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"67859_CR76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","volume":"32","author":"X Luan","year":"2024","unstructured":"Luan, X. et al. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8(+) T cell activity. Mol. Ther. 32, 469\u2013489 (2024).","journal-title":"Mol. Ther."},{"key":"67859_CR77","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1158\/1078-0432.CCR-22-3273","volume":"29","author":"W Yuan","year":"2023","unstructured":"Yuan, W. et al. Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages. Clin. Cancer Res. 29, 3779\u20133792 (2023).","journal-title":"Clin. Cancer Res."},{"key":"67859_CR78","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-22-3645","volume":"83","author":"D Rohila","year":"2023","unstructured":"Rohila, D. et al. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma. Cancer Res. 83, 2675\u20132689 (2023).","journal-title":"Cancer Res."},{"key":"67859_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"67859_CR80","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1039\/C4MT00004H","volume":"6","author":"NP Becker","year":"2014","unstructured":"Becker, N. P. et al. Hypoxia reduces and redirects selenoprotein biosynthesis. Metallomics 6, 1079\u20131086 (2014).","journal-title":"Metallomics"},{"key":"67859_CR81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42003-024-05826-1","volume":"7","author":"C Chai","year":"2024","unstructured":"Chai, C. et al. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Commun. Biol. 7, 131 (2024).","journal-title":"Commun. Biol."},{"key":"67859_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ijgo.12614","volume":"143","author":"JS Berek","year":"2018","unstructured":"Berek, J. S., Kehoe, S. T., Kumar, L. & Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 143, 59\u201378 (2018).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"67859_CR83","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","volume":"40","author":"CM Anadon","year":"2022","unstructured":"Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545\u2013557.e13 (2022).","journal-title":"Cancer Cell"},{"key":"67859_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"67859_CR85","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","volume":"27","author":"CM Laumont","year":"2021","unstructured":"Laumont, C. M. et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer. Clin. Cancer Res. 27, 4089\u20134100 (2021).","journal-title":"Clin. Cancer Res."},{"key":"67859_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36310-9","volume":"14","author":"XZ Huang","year":"2023","unstructured":"Huang, X. Z. et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat. Commun. 14, 822 (2023).","journal-title":"Nat. Commun."},{"key":"67859_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng, Y. et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268 (2020).","journal-title":"Nat. Commun."},{"key":"67859_CR88","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979\u2013982 (2017).","journal-title":"Nat. Methods"},{"key":"67859_CR89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309\u2013315 (2017).","journal-title":"Nat. Methods"},{"key":"67859_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn5683","volume":"8","author":"M Tang","year":"2022","unstructured":"Tang, M. et al. Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Sci. Adv. 8, eabn5683 (2022).","journal-title":"Sci. Adv."},{"key":"67859_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-07739-3","volume":"22","author":"S Kurtenbach","year":"2021","unstructured":"Kurtenbach, S., Cruz, A. M., Rodriguez, D. A., Durante, M. A. & Harbour, J. W. Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data. BMC Genomics 22, 419 (2021).","journal-title":"BMC Genomics"},{"key":"67859_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).","journal-title":"Nat. Commun."},{"key":"67859_CR93","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","volume":"4","author":"Y Mei","year":"2023","unstructured":"Mei, Y. et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. Nat. Cancer 4, 1273\u20131291 (2023).","journal-title":"Nat. Cancer"},{"key":"67859_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell 43, 86\u2013102.e10 (2025).","journal-title":"Cancer Cell"},{"key":"67859_CR95","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12929-022-00888-x","volume":"29","author":"SC Lin","year":"2022","unstructured":"Lin, S. C. et al. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-\u03baB and TGF-\u03b22 signaling. J. Biomed. Sci. 29, 109 (2022).","journal-title":"J. Biomed. Sci."},{"key":"67859_CR96","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/s41588-025-02236-9","volume":"57","author":"T Zhou","year":"2025","unstructured":"Zhou, T. et al. Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression. Nat. Genet. 57, 1935\u20131949 (2025).","journal-title":"Nat. Genet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67859-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:04:42Z","timestamp":1769612682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67859-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67859"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67859-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1097"}}